In the neoadjuvant setting, several clinical trials have been conducted to evaluate the effectiveness of anti-HER2 therapies for localized breast cancer, using the same anti-HER2 therapies initially approved in the metastatic setting [19,20,21,22,23]. This evidence concerns the gene ERBB2 and breast cancer.